Favorable/Unfavorable risk indicator-Unfavorable Posts on Medivizor
Navigation Menu

Favorable/Unfavorable risk indicator-Unfavorable Posts on Medivizor

Evaluating the long-term effectiveness and safety of nivolumab and AVD chemotherapy combination in patients with early-stage unfavorable classical Hodgkin lymphoma.

Evaluating the long-term effectiveness and safety of nivolumab and AVD chemotherapy combination in patients with early-stage unfavorable classical Hodgkin lymphoma.

Posted by on Sep 17, 2023 in Hodgkin's lymphoma | 0 comments

In a nutshell This study reported the long-term safety and effectiveness of nivolumab (Opdivo; N) + AVD (doxorubicin, vinblastine, and dacarbazine) chemotherapy combinations in patients with early-stage unfavorable classical Hodgkin lymphoma (cHL). The data showed that the N+AVD combination is safe and highly effective over the long term for these...

Read More

Evaluating the long-term outcomes of patients with HL receiving intensified treatment

Evaluating the long-term outcomes of patients with HL receiving intensified treatment

Posted by on Jul 31, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to evaluate the long-term effectiveness and safety of high-dose chemotherapy (HDC) for the treatment of patients with unfavorable Hodgkin lymphoma (HL). The authors concluded that HDC increased the control of the disease in the long-term. Some background HDC with radiotherapy is a standard treatment of HL. 4 cycles of...

Read More

Does combining brentuximab vedotin with chemotherapy reduce the risk of consolidative radiotherapy for patients with early-stage unfavorable-risk Hodgkin lymphoma?

Does combining brentuximab vedotin with chemotherapy reduce the risk of consolidative radiotherapy for patients with early-stage unfavorable-risk Hodgkin lymphoma?

Posted by on Jun 6, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated whether brentuximab vedotin (Adcedris; BC) + AVD (doxorubicin, vinblastine, and dacarbazine) chemotherapy combination resulted in a reduction or elimination of consolidative radiotherapy in early-stage unfavorable-risk Hodgkin lymphoma (HL). The data showed that the BV+AVD combination with and without...

Read More

Is PET-guided exclusion of radiotherapy an appropriate treatment regimen for unfavorable early-stage Hodgkin lymphoma?

Is PET-guided exclusion of radiotherapy an appropriate treatment regimen for unfavorable early-stage Hodgkin lymphoma?

Posted by on Mar 21, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell The authors investigated the impact of removing radiotherapy (RT) from treatment regimens in patients with early-stage unfavorable Hodgkin lymphoma (HL). This study concluded that this treatment regimen is just as effective as the standard of care.  Some background Chemotherapy and consolidation RT is the standard of care for...

Read More

Evaluating the effectiveness of brentuximab vedotin and AVD chemotherapy combination in high-risk patients with advanced classical Hodgkin lymphoma

Evaluating the effectiveness of brentuximab vedotin and AVD chemotherapy combination in high-risk patients with advanced classical Hodgkin lymphoma

Posted by on Feb 21, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study compared the long-term safety and effectiveness of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and brentuximab vedotin (Adcedris; A) + AVD (doxorubicin, vinblastine, and dacarbazine) chemotherapy combinations in high-risk patients with advanced classical Hodgkin lymphoma (cHL). The data showed that the A+AVD...

Read More

Pembrolizumab followed by AVD treatment in newly diagnosed advanced classical Hodgkin lymphoma

Pembrolizumab followed by AVD treatment in newly diagnosed advanced classical Hodgkin lymphoma

Posted by on Oct 25, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of pembrolizumab (Keytruda) followed by AVD (doxorubicin, vinblastine, and dacarbazine) treatment in patients with high-risk classical Hodgkin lymphoma.  This study concluded that this treatment was safe and effective in these patients.   Some...

Read More

Does biosimilar filgrastim improve neutropenia in older DLBCL patients receiving chemotherapy?

Posted by on Dec 20, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study analyzed the outcomes of older patients with stage 3 or 4 DLBCL (diffuse large B-cell lymphoma) who received biosimilar filgrastim (Neupogen) during their chemotherapy. The study concluded that filgrastim was safe and effective in these patients. Some background Diffuse large B-cell lymphoma (DLBCL) is the most common type...

Read More

Nivolumab: a new treatment option for Hodgkin lymphoma that has relapsed or not responded to treatment

Nivolumab: a new treatment option for Hodgkin lymphoma that has relapsed or not responded to treatment

Posted by on Dec 20, 2016 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined the use of nivolumab (Opdivo) in patients with heavily pretreated Hodgkin lymphoma. The authors concluded that nivolumab was effective and safe in these patients. Some background PD-1 is a protein that slows the immune response. Many cancer cells use the PD-1 pathway to block the immune system from attacking...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor